A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 124
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : H2RAs
Long Form : histamine-2 receptor antagonists
No. Year Title Co-occurring Abbreviation
2020 Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model. CDIs, CI, HR, PPIs
2020 Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison. GARD, PPIs
2020 Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. PPIs
2020 Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. PPIs
2020 Prophylactic use of acid suppressants in adult acutely ill hospitalised patients: A systematic review with meta-analysis and trial sequential analysis. GI, HRQoL, PPIs, SAEs, SUP, TSA
2020 Use of Proton Pump Inhibitors Increases Risk of Incident Kidney Stones. HR, PPIs
2019 Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists. GLP-1RAs, PPIs
2019 Clostridium Difficile Infection: The Effects of Acid Suppression Therapy in Patients With Cancer. CDI, PPIs
2019 Effect of Gastric Acid Suppressants on Response to a Physical Activity Intervention and Major Mobility Disability in Older Adults: Results from the Lifestyle Interventions for Elders (LIFE) Study. CI, HR, LIFE, PA, PPIs
10  2019 Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. CIs, GI, GPAs, NSAIDs, PPIs
11  2019 Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis. CI, ESD, OR, PPIs
12  2019 Re-evaluating the Utility of Stress Ulcer Prophylaxis in the Critically Ill Patient: A Clinical Scenario-Based Meta-Analysis. CDAD, CI, EGDT, ICU, PPIs, RR, SUP, TSA
13  2019 Stress ulcer prophylaxis in critically ill children: Protocol for a systematic review. GRADE, ICU, PPIs, PRISMA
14  2019 Stress ulcer prophylaxis with proton pump inhibitors or histamin-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. CI, Cl, GI, HRQoL, ICU, PPIs, SAEs, TSA
15  2019 Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: A meta-analysis. CI, GASs, OR, PD, PPIs
16  2018 A Nationwide Population-Based Cohort Study of Dementia Risk Among Acid Suppressant Users. CIs, HRs, PPIs
17  2018 Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. OAC, OR, PPIs
18  2018 ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. GI, PPIs
19  2018 Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients. NSCLC, PFS, TKIs
20  2018 Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. OR, PPIs
21  2018 Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. CIB, OR, PPIs, RCTs, SUP
22  2018 H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review. DAPT, GI, HTPR, MACE, PPIs
23  2018 No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014). CIs, MI, PPIs, RD
24  2018 Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists. PPIs
25  2018 Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. HRs, ORs, PCCIU, PPIs
26  2018 Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis. AD, aORs, CIs, CPRD, PPIs, VaD
27  2018 The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013. CIs, PPIs, PSSA, SR
28  2017 Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. GERD, OR, PPIs
29  2017 Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. GERD, OR, PPIs
30  2017 Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study. CIs, ORs, PPIs
31  2017 Comparison of prophylactic effect of UGIB and effects on platelet function between PPIs and H2RAs combined with DAPT: systematic review and meta-analysis. CIs, DAPT, MACEs, MDs, PPIs, RRs, UGIB
32  2017 Cost-Effectiveness of Histamine2 Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients. ICU, PPIs
33  2017 Drug-Induced Vitamin B12 Deficiency: A Focus on Proton Pump Inhibitors and Histamine-2 Antagonists. PPIs, ZES
34  2017 Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system. GERD, ITT, PP, PPIs, RCTs
35  2017 Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer. PPIs
36  2017 Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. CD, IBD, PPIs, UC
37  2017 Implementation of a Guideline to Decrease Use of Acid-Suppressing Medications in the NICU. PPIs
38  2017 Need for a Randomized Controlled Trial of Stress Ulcer Prophylaxis in Critically Ill Children: A Canadian Survey. PPIs, RCTs
39  2017 PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis. GI, LDA, PPIs
40  2017 Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency. PPIs
41  2017 Stress ulcer prophylaxis versus placebo or no prophylaxis in adult hospitalised acutely ill patients-protocol for a systematic review with meta-analysis and trial sequential analysis. GRADE, ICU, PPIs, PRISMA
42  2017 The impact of acid suppression medications and non-steroidal anti-inflammatory drugs on clinical and histologic features in celiac disease. CD, NSAIDs, PPIs, VF
43  2017 The risk of lower gastrointestinal bleeding in low-dose aspirin users. CI, HR, LGIB, NSAIDs, PPIs, SSRIs
44  2016 Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center. AST, CDAD, HAP, OR, PPIs, SUP
45  2016 Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. GI, GRADE, MD, PPIs, RCTs
46  2016 Gastroprotective effects of several H2RAs on ibuprofen-induced gastric ulcer in rats. LPO, MPO, ROS
47  2016 Non-prescription proton-pump inhibitors for self-treating frequent heartburn:the role of the Canadian pharmacist. PPIs
48  2016 Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. CDI, CI, OR, PPIs, SUP
49  2016 Risk of seizure associated with use of acid-suppressive drugs: An observational cohort study. CIs, OR, ORs, PPIs
50  2015 Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. BMD, BMI, HT, PPIs, SWAN
51  2015 Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression. IQR, PPIs
52  2015 Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. CDAD, PPIs
53  2015 Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. PPIs
54  2015 Risk of spontaneous bacterial peritonitis associated with gastric Acid suppression. aRR, GAS, LC, PPIs, SBP
55  2015 Risk of Stroke-Associated Pneumonia With Acid-Suppressive Drugs: A Population-Based Cohort Study. CI, HRs, PPIs, SAP
56  2015 Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. CDI, CI, OR, PPIs
57  2015 [Role of acid in functional dyspepsia]. FD, JSGE, PPIs
58  2014 Altered mental status in older adults with histamine2-receptor antagonists: a population-based study. CKD, CT
59  2014 Association of Clostridium difficile infections with acid suppression medications in children. CDIs, PPIs, RIs
60  2014 Efficacy and safety of histamine-2 receptor antagonists. GERD
61  2014 Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications. ACG, OTC, PPIs
62  2014 Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. CDI, GI, PPIs
63  2014 Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. OTC
64  2014 Proton pump inhibitor prescribing and costs in a large outpatient clinic. GERD, PPIs
65  2014 Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. CI, OR, PPIs
66  2014 Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: clinical and economic consequences. PPIs, SUP
67  2013 Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. ORs, PPIs
68  2013 Retrospective analysis to investigate the effect of concomitant use of gastric acid-suppressing drugs on the efficacy and safety of pancrelipase/pancreatin (CREON) in patients with pancreatic exocrine insufficiency. CFA, PPIs
69  2013 Risk factors for falls with use of acid-suppressive drugs. CI, CNS, OR, PPIs
70  2013 The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. CDI, NNH
71  2013 The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. GI, NSAIDs
72  2012 Prediction and prevention of upper gastrointestinal bleeding after cardiac surgery: a case control study. GI, PPIs, UGIB
73  2012 Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study. aIRR, CI, PPIs
74  2012 Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. CDI, CI, OR, PPIs
75  2011 Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. ASA, CI, PPIs, RR, UGIB
76  2011 Meta-analysis: risk of fractures with acid-suppressing medication. OR, PPIs
77  2011 Risk of fracture and pneumonia from acid suppressive drugs. OR, PPIs
78  2011 Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents. PPIs
79  2010 Drug utilization patterns in pregnant women: a case study at the Mount Hope Women's Hospital in Trinidad, West Indies. OTC
80  2010 Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. CI, OR, PPIs
81  2009 Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. GERD, OTC, PPI
82  2009 Prescribing pattern of acid suppressive medications for medical inpatients in a teaching hospital in Qatar. ASMs, PPIs
83  2009 The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. BE, GERD, MOR, PPIs
84  2007 Nonsteroidal, antiinflammatory drug-induced gastrointestinal injuries and related adverse reactions: epidemiology, pathogenesis and management. ASA, COX, NSAIDs, PPIs, PUD, ROS
85  2007 Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers. GERD, IM, PPIs
86  2007 Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. CI, GE, PPIs, RR
87  2006 The long-term natural history of gastroesophageal reflux disease. CI, GER, NSAID, OR, PPIs
88  2005 A 9 year prospective cohort study of endoscoped patients with upper gastrointestinal symptoms. PPIs
89  2005 Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. GERD, PPI
90  2005 Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine. i.v, PPIs
91  2005 PPI use in the OTC era: who to treat, with what, and for how long? GERD, OTC, PPIs
92  2005 Preventing the gastrointestinal consequences of stress-related mucosal disease. GI, PPIs, SRMD
93  2004 Consumer usage patterns of nonprescription histamine2-receptor antagonists. OTC, PPIs
94  2004 Nocturnal acid breakthrough - approach to management. GERD, PPI
95  2004 Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population. PPIs
96  2003 Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. PPIs, UGI
97  2003 History of acid suppression: focus on the hospital setting. PPIs
98  2003 Predictive factors of the long-term outcome in reflux esophagitis in a low-prevalence gastroesophageal reflux disease region. LA, PPIs
99  2003 Short-term treatment of gastroesophageal reflux disease. ENRD, GERD, PPIs, SRR
100  2003 Treating patients with acute gastrointestinal bleeding or rebleeding. PPIs